Parmax Pharma Ltd

Parmax Pharma, a microcap pharmaceutical company, has reported a significant improvement in its financial performance for the second quarter of fiscal year 2024-2025. The company's net sales have increased by 212.61% year on year, surpassing the sales of the entire previous year. This indicates a strong and positive sales trend for Parmax Pharma.

Parmax Pharma, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 27, 2024. The stock has gained for six consecutive days, with a 27.32% increase. Despite a 'Sell' call from MarketsMOJO, the stock is trading higher than its moving averages, indicating a positive trend. In the past year, Parmax Pharma has outperformed the market, showcasing its potential for growth.

Parmax Pharma, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 26, 2024. The stock has outperformed its sector by 4.92% and gained 22.71% in the last 5 days. It is currently trading above all its moving averages and has shown a consecutive gain streak. However, MarketsMOJO has given a 'Sell' call for the stock, possibly due to market conditions or the company's financial performance. Investors should conduct their own research before making any investment decisions.

Parmax Pharma, a microcap pharmaceutical company, saw its stock price hit a 52-week high of Rs. 49.21 on September 25th, 2024. The stock has outperformed the sector by 4.89% and has been on a consecutive gain streak for the last 4 days, with a total return of 16.89%. The company's stock is currently trading above its moving averages and has shown a strong 1-year performance of 50.58% compared to the Sensex's 28.59%. This news highlights the company's positive growth and potential in the market.

Parmax Pharma, a microcap pharmaceutical company, has reported a flat performance in the first quarter of 2024, but has shown an improvement in its score from -16 to 4 in the last three months. The company's net sales have grown by 55.27% year on year and its profitability has also improved, with its operating profit, profit before tax, and profit after tax reaching their highest in the last five quarters. However, the company's debtors turnover ratio has decreased, indicating a slower pace in settling debts. Overall, Parmax Pharma has a positive trend in its financial performance and is expected to continue its growth in the near future.

Parmax Pharma, a microcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on July 18, 2024. The stock has been gaining for the past two days, with a rise of 19.02% in returns. It opened with a significant gain of 13.74% and is currently trading higher than its moving averages, showcasing its strong growth and potential in the industry.

Parmax Pharma, a microcap pharmaceutical company, has reached a new 52-week high on July 15, 2024. The stock has outperformed the sector by 9.5% and has gained 25.44% in the last two days. It has also shown impressive performance over the past year, with a 45.73% increase compared to the Sensex.

Parmax Pharma, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 12, 2024. The stock has outperformed its sector by 14.12% today, with a gain of 5.26% and an intraday high of Rs 38.99. The company's moving averages and past year's growth showcase its strong performance, but MarketsMOJO has given a 'Strong Sell' call for the stock.

Parmax Pharma, a microcap pharmaceutical company, reached a 52-week high on May 10, 2024, showing strong performance in the market. Despite a Strong Sell rating from MarketsMOJO, the stock outperformed the sector by -5.89% and is currently trading higher than its moving averages. With a 7.75% increase in the past year, Parmax Pharma has maintained steady growth in the challenging pharmaceutical industry.

Parmax Pharma, a microcap pharmaceutical company, has hit a 52-week low and received a 'Strong Sell' rating from MarketsMOJO. The stock is currently trading below its moving averages and has underperformed the pharma sector. Investors should approach with caution and conduct thorough research before considering Parmax Pharma as an investment option.

Parmax Pharma, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023. The company's Profit Before Tax, Operating Profit, Profit After Tax, and Net Sales have all decreased, indicating a negative trend in the near term. MarketsMOJO has given a 'Strong Sell' call for the company's stock.

Parmax Pharma, a microcap pharmaceutical company, has been downgraded to a 'Sell' rating by MarketsMOJO due to its weak long-term fundamentals, low growth in net sales and operating profit, and struggles with debt management. The company's recent quarter performance has also been lackluster, reflected in its -14.63% stock return in the last year. Technical indicators are mildly bullish, but the majority of shareholders are non-institutional, indicating a lack of confidence in the company's future.

Parmax Pharma, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO. The stock has shown a bullish trend and has improved from a mildly bullish position on January 15, 2024. However, the company's majority shareholders are non-institutional and it has weak long-term fundamentals, making it a 'Hold' for investors.

Parmax Pharma, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to its weak long-term fundamental strength, operating losses, and poor growth in net sales and operating profit. The company's ability to service its debt is also a concern, with a low EBIT to Interest ratio. Despite some bullish indicators and attractive valuation, the stock has consistently underperformed in the long-term and near-term, making it a cause for caution for potential investors.

Parmax Pharma, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO, indicating a neutral stance on its performance. The stock has shown technical improvement and is currently trading at a discount. However, weak long-term fundamentals and lack of confidence from larger investors suggest a cautious approach towards investing in the company.

Parmax Pharma, a microcap pharmaceutical company, reported a significant growth of 190.71% in net sales for the quarter ended September 2023. However, standalone net profit and operating profit saw a decline of 16.10% and 16.92% respectively. The stock call is currently 'Strong Sell' and the company's financial performance has been flat with some positive and negative aspects.